NADMED has partnered with London-based Altheome Labs to expand access to advanced NAD testing in the UK, marking another step in the company’s international growth.
Through this collaboration, NADMED’s CE-marked NAD measurement technology will be integrated into Altheome’s biomarker and diagnostics services, enabling clinics to offer accurate and scalable NAD testing.
“We are excited to partner with NADMED to bring this advanced testing capability to our clients,” said Adam Shellard, Founder and CEO of Altheome. “Their technology complements our focus on high-quality biomarker analysis and supports our mission to deliver meaningful insights for clinicians and their patients.”
“We are pleased to collaborate with Altheome to make our NAD testing technology available in the UK,” commented Jari Närhi, CEO and Co-Founder of NADMED. “Combining our validated measurement platform with Altheome’s expertise helps ensure strong implementation and impact in clinical use.”
The partnership supports NADMED’s mission to establish NAD as a key biomarker in precision medicine and to make high-quality metabolic insights available to a broader clinical and research audience.
If you are interested in getting your NADs tested in the UK, please visit here.
Read the press release here.